ADMELOG A NEW INSULIN  LISPRO OPTION

A MEALTIME INSULIN highly similar to Humalog® in structure, pharmacology, efficacy, safety, and dosing1-4

FOR DETAILS, VISIT ADMELOGPRO.COM

Indication for ADMELOG® (insulin lispro injection) 100 Units/mL ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes and adults and children (3 years and older) with type 1 diabetes. Important Safety Information for ADMELOG® (insulin lispro injection) 100 Units/mL CONTRAINDICATIONS ADMELOG is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro or to any of its excipients. WARNINGS AND PRECAUTIONS Insulin pens and needles must never be shared between patients, even if the needle is changed. Do NOT reuse needles. Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia. Hypoglycemia is the most common adverse reaction associated with insulins, including ADMELOG, and may be life-threatening. Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between ADMELOG and other insulins, instruct patients to always check the insulin label before each injection. Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including ADMELOG. If hypersensitivity reactions occur, discontinue ADMELOG, treat per standard of care and monitor until symptoms and signs resolve. All insulin products, including ADMELOG, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia. Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs. ADVERSE REACTIONS Adverse reactions associated with ADMELOG include hypoglycemia, hypokalemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema. DRUG INTERACTIONS Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine). IMPORTANT SAFETY INFORMATION FOR ADMELOG (INSULIN LISPRO INJECTION) SOLOSTAR ADMELOG SoloSTAR is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. Click here for Full Prescribing Information. Click here for information on Sharps Medical Waste Disposal. Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs. References: 1. ADMELOG Prescribing Information. 2. Humalog Prescribing Information. 3. Kapitza C, Nowotny I, Lehmann A, et al. Diabetes Obes Metab. 2017;19(5):622-627. 4. Garg, SK, Wernicke-Panten K, Rojeski M, Pierre S, Kirchhein Y, Jedynasty K. Diabetes Technol Ther. 2017; 19(9):516-526. Epub 2017 Aug 30. ADMELOG is a registered trademark of sanofi-aventis U.S. LLC. Humalog is a registered trademark of Eli Lilly and Company.